Generated by All in One SEO v4.9.9, this is an llms.txt file, used by LLMs to index the site. # Contineum Therapeutics Life Reconnected. ## Sitemaps - [XML Sitemap](https://contineum-tx.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders](https://contineum-tx.com/publications/discovery-of-pipe-791-a-potent-and-brain-penetrant-lysophosphatidic-acid-receptor-1-antagonist-with-slow-tight-binding-characteristics-for-the-treatment-of-neuroinflammatory-disorders/) - [LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro](https://contineum-tx.com/publications/lpa1-antagonism-by-pipe-791-reduces-alveolar-epithelial-cell-apoptosis-in-vitro/) - [PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists with Distinct Lung Occupancy Profiles and Vascular Effects](https://contineum-tx.com/publications/pipe-791-and-bms-986278-two-lysophosphatidic-acid-receptor-1-lpa1-antagonists-with-distinct-lung-occupancy-profiles-and-vascular-effects/) - [LPA1 Expression in CNS Fibroblasts During Multiple Sclerosis](https://contineum-tx.com/publications/lpa1-expression-in-cns-fibroblasts-during-multiple-sclerosis/) - [Exploring the Effects of SARM1 Inhibition in Preventing Neurodegeneration in Human and Rodent Neuropathic Pain Models](https://contineum-tx.com/publications/exploring-the-effects-of-sarm1-inhibition-in-preventing-neurodegeneration-in-human-and-rodent-neuropathic-pain-models/) - [VP, Head of Biometrics](https://contineum-tx.com/open-positions/vp-head-of-biometrics/) - [The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis](https://contineum-tx.com/publications/the-lpar1-antagonist-pipe-791-produces-antifibrotic-effects-in-models-of-lung-fibrosis/) - [CNS-Penetrant LPA₁ Antagonist PIPE-791 Provides Superior Analgesia Compared to Peripherally-Restricted CTX-343 in a Rat Model of LPA-Induced Osteoarthritis](https://contineum-tx.com/publications/cns-penetrant-lpa₁-antagonist-pipe-791-provides-superior-analgesia-compared-to-peripherally-restricted-ctx-343-in-a-rat-model-of-lpa-induced-osteoarthritis/) - [LPA-Induced Activation of Satellite Glial Cells and Its Modulation by PIPE-791, a novel LPA1 antagonist, in an In Vitro Pain Model](https://contineum-tx.com/publications/lpa-induced-activation-of-satellite-glial-cells-and-its-modulation-by-pipe-791-a-novel-lpa1-antagonist-in-an-in-vitro-pain-model/) - [LPA1 receptor binding sites are abundant in multiple sclerosis patient rim lesions associated with TSPO activation and disease progression](https://contineum-tx.com/publications/lpa1-receptor-binding-sites-are-abundant-in-multiple-sclerosis-patient-rim-lesions-associated-with-tspo-activation-and-disease-progression/) - [Active MS lesions are characterized by high LPA1 expression and PIPE-791 promotes remyelination via LPA1 inhibition in the cuprizone model](https://contineum-tx.com/publications/active-ms-lesions-are-characterized-by-high-lpa1-expression-and-pipe-791-promotes-remyelination-via-lpa1-inhibition-in-the-cuprizone-model/) - [Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis](https://contineum-tx.com/publications/discovery-of-a-brain-penetrant-small-molecule-antagonist-targeting-lpa1-receptors-to-reduce-neuroinflammation-and-promote-remyelination-in-multiple-sclerosis/) - [The muscarinic M1 antagonist PIPE-359 demonstrates remyelination in vivo through visual evoked potential (VEP) and electron microscopy (EM) of mice with experimental autoimmune encephalitis (EAE)](https://contineum-tx.com/publications/the-muscarinic-m1-antagonist-pipe-359-demonstrates-remyelination-in-vivo-through-visual-evoked-potential-vep-and-electron-microscopy-em-of-mice-with-experimental-autoimmune-encephalitis-eae/) - [Small molecule inhibition of the muscarinic M1 acetylcholine receptor by potent, selective antagonists facilitate OPC differentiation](https://contineum-tx.com/publications/small-molecule-inhibition-of-the-muscarinic-m1-acetylcholine-receptor-by-potent-selective-antagonists-facilitate-opc-differentiation/) - [PIPE-359, a novel, potent and selective M1 muscarinic receptor antagonist as a therapeutic approach for remyelination in multiple sclerosis](https://contineum-tx.com/publications/pipe-359-a-novel-potent-and-selective-m1-muscarinic-receptor-antagonist-as-a-therapeutic-approach-for-remyelination-in-multiple-sclerosis/) - [Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE](https://contineum-tx.com/publications/discovery-of-pipe-359-a-brain-penetrant-selective-m1-receptor-antagonist-with-robust-efficacy-in-murine-mog-eae/) - [Discovery of a Novel M1 Selective Antagonist, PIPE-307, for the Treatment of Multiple Sclerosis](https://contineum-tx.com/publications/discovery-of-a-novel-m1-selective-antagonist-pipe-307-for-the-treatment-of-multiple-sclerosis/) - [PIPE-307, a brain penetrant M1 selective antagonist, exhibits scopolamine-like antidepressive effects](https://contineum-tx.com/publications/pipe-307-a-brain-penetrant-m1-selective-antagonist-exhibits-scopolamine-like-antidepressive-effects/) - [Lysolecithin (LPC) induced demyelination of the optic chiasm as a model to evaluate remyelinating agents](https://contineum-tx.com/publications/lysolecithin-lpc-induced-demyelination-of-the-optic-chiasm-as-a-model-to-evaluate-remyelinating-agents/) - [Characterization of M1 Selective and Brain Penetrant [11 C] PIPE 307 PET Radiotracer in Cynomolgus Monkeys](https://contineum-tx.com/publications/characterization-of-m1-selective-and-brain-penetrant-11-c-pipe-307-pet-radiotracer-in-cynomolgus-monkeys/) - [PIPE-791, a potent brain-penetrant selective LPA1 antagonist, reduces neuroinflammation in vivo ](https://contineum-tx.com/publications/pipe-791-a-potent-brain-penetrant-selective-lpa1-antagonist-reduces-neuroinflammation-in-vivo/) - [Discovery of remyelination therapeutics that overcome the effects of inflammatory macrophages on oligodendrocyte formation](https://contineum-tx.com/publications/discovery-of-remyelination-therapeutics-that-overcome-the-effects-of-inflammatory-macrophages-on-oligodendrocyte-formation/) - [PIPE-791 inhibits LPA1 to promote myelination and limit neuroinflammation](https://contineum-tx.com/publications/pipe-791-inhibits-lpa1-to-promote-myelination-and-limit-neuroinflammation/) - [Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis](https://contineum-tx.com/publications/targeting-the-muscarinic-m1-receptor-with-a-selective-brain-penetrant-antagonist-to-promote-remyelination-in-multiple-sclerosis/) - [Lysophosphatidic Acid Receptor Subtype-1 Antagonist PIPE-791 Reduces Neuropathic Pain in Macaques](https://contineum-tx.com/publications/lysophosphatidic-acid-receptor-subtype-1-antagonist-pipe-791-reduces-neuropathic-pain-in-macaques/) ## Pages - [Home](https://contineum-tx.com/) - We are pioneering new therapies for conditions at the intersection of NI&I. - [Patients & Caregivers](https://contineum-tx.com/patients-and-caregivers/) - People living with neurological, inflammatory and fibrotic diseases are at the center of Contineum’s mission. - [Our Science](https://contineum-tx.com/our-science/) - Our team is developing drug candidates that primarily focus on de-risked, clinically validated targets—biological pathways already shown to play a key role across a range of conditions. - [About](https://contineum-tx.com/about/) - Our mission is to make a meaningful difference in the clinical disability associated with neurology, inflammation and immunology (NI&I) diseases. - [Careers](https://contineum-tx.com/careers/) - At Contineum Therapeutics, advancing science and research to improve patient lives requires a diversity of talents, personalities, character traits and expertise. - [Connect](https://contineum-tx.com/connect/) - Contact us if you are interested in learning more about our clinical trials, partnering with us or have a general inquiry. - [Pipeline](https://contineum-tx.com/pipeline/) - Small molecule drug candidates designed to address the underlying causes of disease. - [Publications](https://contineum-tx.com/pipeline/publications/) - View our latest publications. - [Footer](https://contineum-tx.com/footer/) - [Terms of Use](https://contineum-tx.com/terms-of-use/) - Contineum Tx Terms of Use - [Privacy Policy](https://contineum-tx.com/privacy-policy/) - Contineum Tx Privacy Policy ## Categories - [Open Positions](https://contineum-tx.com/category/open-positions/) - [Publications](https://contineum-tx.com/category/publications/) - [2024](https://contineum-tx.com/category/publications/2024/) - [2023](https://contineum-tx.com/category/publications/2023/) - [2022](https://contineum-tx.com/category/publications/2022/) - [2021](https://contineum-tx.com/category/publications/2021/) - [2020](https://contineum-tx.com/category/publications/2020/) - [2019](https://contineum-tx.com/category/publications/2019/) - [2025](https://contineum-tx.com/category/publications/2025/) - [2026](https://contineum-tx.com/category/publications/2026/) ## Portfolio Categories - [Leadership](https://contineum-tx.com/team/leadership/) - [Board of Directors](https://contineum-tx.com/team/board-of-directors/)